TRPA1 and myeloid sarcoma: Considering the attractiveness of such strategies for discovering novel therapeutic solutions using repurposable drug candidates [50], we performed in silico screening studies based on chemical graph mining, classification and regression quantitative structure–activity relationship (QSAR) modeling, and molecular docking techniques in order to identify approved drugs as potent TRPA1 antagonists that may serve as potential treatments for MS patients.